Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Estimation of the VQ11 Auto-questionnaire, to Follow Patients With Chronic Obstructive Pulmonary Disease (EPIC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01651676
Recruitment Status : Completed
First Posted : July 27, 2012
Last Update Posted : August 10, 2018
Sponsor:
Information provided by (Responsible Party):
Centre Hospitalier Universitaire, Amiens

Brief Summary:

The purpose of this study is to estimate the capacity of the auto-questionnaire of quality of life, VQ11, to follow the evolution of patients with COPD (Chronic obstructive pulmonary disease) in stable state (without exacerbation in the previous 6 weeks) (3 months +/-15 days) during the implementation of a LABD (Long-acting bronchodilator) treatment.

The main objective is to compare the total Score of the VQ11 auto-questionnaire before and after LABD. A decrease of 5 points of the total score mimicking an improvement in the quality of life linked to health, specifically in the COPD.


Condition or disease Intervention/treatment Phase
COPD Other: VQ11 validation Not Applicable

Detailed Description:

Evaluation of the VQ11 auto-questionnaire of quality of life in pneumology investigation, during the implementation of a long-acting bronchodilator treatment of patients with COPD.

Two visits per patient are planned:

V1: After complete information and collection of the written consent, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, 2 visual analogical scales concerning the dyspnoea and the physical activity, the short IPAQ version and the respiratory questionnaire of the Saint Georges hospital. RFE (respiratory functional exploration) is also realized during this medical exam.

V2 (3 months after the treatment setup, at day90 ± 15): the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, 2 visual analogical scales and Likert scales concerning the dyspnoea and the physical activity, the short IPAQ version and the respiratory questionnaire of the Saint Georges hospital. RFE (respiratory functional exploration) is also realized during this medical exam.

Inclusion period : 6 months; Study participation period / patient : 3 months; Complete study duration : 9 months

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 57 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Evaluation of the VQ11 Auto-questionnaire of Quality of Life in Pneumology Investigation, During the Implementation of a Long-acting Bronchodilator Treatment of Patients With COPD.
Study Start Date : February 2013
Actual Primary Completion Date : December 2015
Actual Study Completion Date : December 2015

Arm Intervention/treatment
Experimental: COPD arm

VQ11 validation:

Stage II, III or IV COPD patients justifying a LABD will benefit from the studied VQ11 questionnaire

Other: VQ11 validation

Two visits per patient are planned: V1 and V2.

For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)

LABD treatment consist in β 2 agonists or anticholinergic drug.





Primary Outcome Measures :
  1. VQ11 score [ Time Frame: V1 (at baseline), V2 (3 months after V1) ]
    To compare changes of total Score of the VQ11 auto-questionnaire before and after LABD (decrease of 5 points of the total score mimicking an improvement in the quality of life linked to health, specifically in the COPD).


Secondary Outcome Measures :
  1. VQ11 and visual analogical scale regarding daily activity [ Time Frame: V1 (at baseline), V2 (3 months after V1) ]
    To estimate the daily activity by a dedicated visual analogical scale. Variations between the two visits will be analysed in correlation to VQ11 changes.

  2. RFE [ Time Frame: V1 (at baseline), V2 (3 months after V1) ]
    Respiratory functional exploration (RFE) performed at rest (plethysmography) before and three months after LABD treatment initiation.

  3. VQ11 sub-scores [ Time Frame: V1 (at baseline), V2 (3 months after V1) ]
    To estimate the impact of an LABD treatment on patients with COPD before and three months after treatment initiation through the three sub-dimensions of the VQ11 questionnaire

  4. Likert scales [ Time Frame: V2 (3 months after V1) ]
    To estimate the evolution of dyspnoea and the daily activity by Likert scale.

  5. VQ11 and visual analogical scales regarding dyspnoea [ Time Frame: V1 (at baseline), V2 (3 months after V1) ]
    To estimate the dyspnoea by a dedicated visual analogical scale. Variations between the two visits will be analysed in correlation to VQ11 changes.

  6. Bi-directional visual analogical scale regarding dyspnoea [ Time Frame: V2 (3 months after V1) ]
    To estimate the evolution of dyspnoea since the LABD initiation.

  7. Bi-directional visual analogical scale regarding daily activity [ Time Frame: V2 (3 months after V1) ]
    To estimate the evolution of daily activity since the LABD initiation.

  8. Saint George's Respiratory Questionnaire [ Time Frame: V1 (at baseline), V2 (3 months after V1) ]
    To estimate the impact of an LABD treatment on patients with COPD before and three months after treatment initiation using the SGRQ change between the two visits.

  9. Dyspnoea evolution assessed by mMRC [ Time Frame: V1 (at baseline), V2 (3 months after V1) ]
    To estimate the impact of the LABD treatment on dyspnoea of patients with COPD before and three months after treatment initiation through the change of the Modified Medical Research Council dyspnoea scale (mMRC).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • COPD patient with stage II, III ou IV justifying a LABD
  • Patient in stable state (without exacerbation in the previous 6 weeks)
  • Clinical criteria: dyspnoea stage I ou more (MMRC scale)
  • Adult over 18 years old.
  • Patients naïve from LABD treatment.

Exclusion Criteria:

  • Other associated pathology (bronchiectasia...)
  • Heart disorder with a prevailing role in the dyspnoea
  • Cardiac decompensation in the previous year
  • Pregnancy and lactating
  • Women in genital activity without efficient contraception method (IUD or estrogen-progestin pill)
  • Lack of social insurance
  • Patient non compliant to protocol, at the investigator's appreciation
  • Simultaneous participation to other clinical trial.
  • adult under judicial protection (tutor or curator).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01651676


Locations
Show Show 17 study locations
Sponsors and Collaborators
Centre Hospitalier Universitaire, Amiens
Investigators
Layout table for investigator information
Principal Investigator: Charles DAYEN, MD University Hospital of Amiens

Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire, Amiens
ClinicalTrials.gov Identifier: NCT01651676    
Other Study ID Numbers: PI2011_843_0006
2011-A01653-38 ( Other Identifier: ID-RCB )
First Posted: July 27, 2012    Key Record Dates
Last Update Posted: August 10, 2018
Last Verified: August 2018
Keywords provided by Centre Hospitalier Universitaire, Amiens:
VQ11 questionnaire
COPD
LBD